Precision Oncology Framework Using Circulating Tumor Cells
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Circulating tumor cells (CTCs) are powerful biomarkers for precision oncology. These cells offer insights into cancer progression and treatment response, potentially outperforming traditional markers.
Area Of Science
- Oncology and Molecular Diagnostics
Background
- Circulating tumor cells (CTCs) are key biomarkers in precision oncology.
- CTCs provide prognostic information during various cancer therapies.
- Tumor heterogeneity in CTCs presents challenges, especially with emerging drug resistance.
Purpose Of The Study
- To highlight the potential of CTCs in refining cancer diagnoses and personalizing treatments.
- To discuss the role of CTCs in monitoring treatment response and prognosis.
- To explore the clinical utility and implementation of CTC assays.
Main Methods
- Review of existing technologies for CTC isolation and analysis.
- Comparison of CTC assays with circulating tumor DNA (ctDNA) tests.
- Evaluation of CTCs as potential tumor markers in colorectal and breast cancer.
Main Results
- CTC assays are reliable prognostic indicators, even during therapy.
- CTCs reflect tumor progression, while ctDNA correlates with tumor burden.
- CTC tests show promise as alternatives or complements to conventional tumor markers like CEA, CA19-9, and CA15-3.
Conclusions
- Dynamic CTC analysis offers valuable insights into treatment efficacy and patient prognosis.
- Combined analysis of CTCs and ctDNA may provide complementary prognostic information.
- Integrating CTC tests into routine blood panels is a rational and promising strategy for improved cancer management.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.